

30 October 2020

Tender results

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of November or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information.

[More information about this process and NOPC forms can be found on our website.](#)

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 12 November 2020 (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

CORRECTION to April 2020 tender notification:

PHARMAC incorrectly notified the pricing relating to the darunavir tab 600 mg tender award. Corrections are in **bold** and strikethrough below.

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Darunavir ¹	Tab 600 mg, 60 tablet bottle pack	\$476.00	\$196.55 \$196.65	Darunavir Mylan (Mylan)	1 November 2020	1 April 2021	Prezista (Janssen-Cilag)
1. Brand switch fee of \$4.50 is payable for this product from 1 April 2021 to 30 June 2021							

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Darunavir	Tab 600 mg, 60 tablet bottle pack	\$476.00	\$196.55 \$196.65	Darunavir Mylan (Mylan)	1%	1 November 2020	1 April 2021	Prezista (Janssen-Cilag)

**2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023 -
October tender notification**

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Omeprazole ^{1,2}	Cap 10 mg; 90 capsule bottle	\$1.98	\$1.94	Omeprazole Actavis 10 (Teva)	1 March 2021	1 August 2021
Omeprazole ^{1,2}	Cap 20 mg; 90 capsule bottle	\$1.96	\$1.86	Omeprazole Actavis 20 (Teva)	1 March 2021	1 August 2021
Omeprazole ²	Cap 40 mg; 90 capsule bottle	\$3.12	\$3.11	Omeprazole Actavis 40 (Teva)	1 March 2021	1 August 2021
Rifaximin	Tab 550 mg; 56 tablet blister pack	\$625.00	\$625.00	Xifaxan (Norgine)	1 December 2020	1 March 2021
<p>1. Please note the Pharmacode and the capsule design will change for these chemicals.</p> <p>2. This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2019/20 Invitation To Tender.</p>						

2. *Tenders awarded to currently listed pharmaceuticals where no brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	New pack price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Latanoprost with timolol	Eye drops 0.005% with timolol 0.5%; 2.5 ml OP	\$2.49	Arrow-Lattim (Teva)	1 April 2021	1 September 2021
Nitrofurantoin	Cap modified-release 100 mg; 100 capsule bottle	\$86.40	Macrobid (Te Arai BioFarma)	1 March 2021	1 August 2021

[The decision to award a tender to nitrofurantoin cap modified-release 100 mg results in the funding of a new formulation of nitrofurantoin for the treatment of uncomplicated urinary tract infections.](#)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Omeprazole ^{1,2}	Cap 10 mg; 90 capsule bottle	\$1.98	\$1.94	Omeprazole Actavis 10 (Teva)	1%	1 March 2021	1 August 2021
Omeprazole ^{1,2}	Cap 20 mg; 90 capsule bottle	\$1.96	\$1.86	Omeprazole Actavis 20 (Teva)	1%	1 March 2021	1 August 2021
Omeprazole ²	Cap 40 mg; 90 capsule bottle	\$3.12	\$3.11	Omeprazole Actavis 40 (Teva)	1%	1 March 2021	1 August 2021

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Rifaximin	Tab 550 mg; 56 tablet blister pack	\$625.00	\$625.00	Xifaxan (Norgine)	1%	1 December 2020	1 March 2021
<p>1. Please note that this will result in a new pharmacode for these products, however these chemicals will continue to be supplied by Teva.</p> <p>2. This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(II) of the 2019/20 Invitation To Tender.</p>							

4. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Latanoprost with Timolol	Eye drops 0.005% with timolol 0.5%; 2.5 ml	\$2.49	Arrow-Lattim (Teva)	1%	1 April 2021	1 September 2021
Nitrofurantoin	Cap modified-release 100 mg; 100 capsule bottle	\$86.40	Macrobid (Te Arai BioFarma)	1%	1 March 2021	1 August 2021

[The decision to award a tender to nitrofurantoin cap modified-release 100 mg results in the funding of a new formulation of nitrofurantoin for the treatment of uncomplicated urinary tract infections.](#)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2018/19 Invitation to Tender, dated 1 November 2018, and
- the 2019/20 Invitation to Tender, dated 1 November 2019

2018/19 Invitation to Tender

Chemical name	Line item
Aciclovir	Eye ointment 3%

2019/20 Invitation to Tender

Chemical name	Line item
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
Ticagrelor	Tab 90 mg

For products included in the 2018/19 and 2019/20 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.